Richard Furie's guest appearances

Richard Furie

Healio Rheuminations

trialsitenews's podcast

Ian Smith

Aaron Levine

Hidradenitis Suppurativa

Stuart Young

Claudia Christian

Theresa Deisher

Martin J. Blaser

John Stone

Michael Weiner

Chris Guccione

Jason Baumgartner

Tom Pitts

Shabnam Palesa Mohamed

Jayne Morgan

Alison Egeland

OwlTail

Dr. Richard Furie discuss his recent involvement with the Phase 3 BLISS-LN clinical trial that is setting the stage for the first ever FDA approved drug for lupus nephritis. Dr. Furie is a professor at the Feinstein Institutes for medical research, Northwell Health’s science arm of the health system. Regarded as one the senior rheumatologists in the New York metropolitan area, he has been on the Boards of Directors of the local chapters of the Arthritis Foundation and the Lupus Alliance of America and has been a member of the Medical-Scientific Advisory Council of the Lupus Foundation of America as well as its Lupus News editorial board. He also is on the Medical and Scientific Advisory Board of the SLE Foundation as well as the Alliance for Lupus Research Scientific Advisory Board.

Dr. Richard Furie discuss his recent involvement with the Phase 3 BLISS-LN clinical trial that is setting the stage for the first ever FDA approved drug for lupus nephritis. Dr. Furie is a professor at the Feinstein Institutes for medical research, Northwell Health’s science arm of the health system. Regarded as one the senior rheumatologists in the New York metropolitan area, he has been on the Boards of Directors of the local chapters of the Arthritis Foundation and the Lupus Alliance of America and has been a member of the Medical-Scientific Advisory Council of the Lupus Foundation of America as well as its Lupus News editorial board. He also is on the Medical and Scientific Advisory Board of the SLE Foundation as well as the Alliance for Lupus Research Scientific Advisory Board.

Dr. Richard Furie Discusses Lupus and Phase 3 BLISS-LN Clinical Trial | Podcast E42

Richard Furie, MD, is chief, division of rheumatology, at Northwell Health, and professor of medicine at Hofstra/Northwell School of Medicine. Join us in this ACR interview, as we discuss the story of interferon, lupus therapeutics — including B cell depletion — and the future of lupus research and treatments.  Intro :10   Background on Dr. Furie :16 The interview :56   What advancements in the pathophysiology of lupus are you most excited about? 1:10 The interferon story 1:23   The interferon story is not finished yet 7:18 Dendritic cells in lupus patients 7:41 What is “interferon signature?” 8:07 Do we see different clinical phenotype in patients with high interferon signature? 9:38   What’s your opinion on the role of B cells? 10:07   Any other pathophysiology mechanisms being used to target B cells? 13:15   Are we stretched thin in terms of number of lupus patients in trials? 15:21   How would designating lupus as an orphan disease change the way it’s investigated? 16:40 What is your main concern regarding study design? 17:37   Looking 10 years ahead, do you think what we call “lupus” will still be referred to as such, or will it be decompartmentalized into different diseases? 21:26 What’s the expense of cytokine profiling? 22:40 What excites you the most about the future of lupus research? 23:21   Thank you, Dr. Furie 24:41 Recap 24:43 Shout out to the 7th Annual Basic and Clinical Immunology for the Busy Clinician: What is New and Hot in Immunology bootcamp in Scottsdale, AZ, Feb. 15-16, 2019 25:31  We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. And be sure to follow us on Twitter @AdamJBrownMD and @HealioRheum. This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.

Richard Furie, MD, is chief, division of rheumatology, at Northwell Health, and professor of medicine at Hofstra/Northwell School of Medicine. Join us in this ACR interview, as we discuss the story of interferon, lupus therapeutics — including B cell depletion — and the future of lupus research and treatments. <ul> <li>Intro :10</li> </ul> <ul> <li>Background on Dr. Furie :16</li> <li>The interview :56</li> <li> <ul> <li>What advancements in the pathophysiology of lupus are you most excited about? 1:10</li> <li>The interferon story 1:23</li> <li> <ul> <li>The interferon story is not finished yet 7:18</li> <li>Dendritic cells in lupus patients 7:41</li> <li>What is “interferon signature?” 8:07</li> <li>Do we see different clinical phenotype in patients with high interferon signature? 9:38</li> </ul> </li> <li>What’s your opinion on the role of B cells? 10:07</li> <li> <ul> <li>Any other pathophysiology mechanisms being used to target B cells? 13:15</li> </ul> </li> <li>Are we stretched thin in terms of number of lupus patients in trials? 15:21</li> <li> <ul> <li>How would designating lupus as an orphan disease change the way it’s investigated? 16:40</li> <li>What is your main concern regarding study design? 17:37</li> </ul> </li> <li>Looking 10 years ahead, do you think what we call “lupus” will still be referred to as such, or will it be decompartmentalized into different diseases? 21:26</li> <li>What’s the expense of cytokine profiling? 22:40</li> <li>What excites you the most about the future of lupus research? 23:21</li> </ul> </li> <li>Thank you, Dr. Furie 24:41</li> <li>Recap 24:43</li> <li>Shout out to the 7th Annual Basic and Clinical Immunology for the Busy Clinician: What is New and Hot in Immunology bootcamp in Scottsdale, AZ, Feb. 15-16, 2019 25:31</li> </ul> We’d love to hear from you! Send your comments/questions to <a href="mailto:rheuminationspodcast@healio.com">rheuminationspodcast@healio.com</a>. And be sure to follow us on Twitter @AdamJBrownMD and @HealioRheum. This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.

The ACR Interviews: Richard Furie, MD